The extraordinary general meeting of Newbury Pharmaceuticals AB took place on 15 April 2026. All decisions made by the general meeting are in accordance with the proposals presented in the notice.
Approval of related party transaction
The general meeting resolved, in accordance with the board's proposal, to approve a related party transaction whereby the loan agreement between Newbury Pharmaceuticals AB and AB Slädens Pensionsstiftelse nr 3, originally entered into on 18 September 2023, was amended. The amendment comprises: (i) a 12-month extension of the loan maturity to 30 June 2027, (ii) an increase of the loan principal by SEK 15 million to a total of SEK 30 million, disbursed within 30 days of signing, and (iii) a new clause requiring the lender’s prior written consent for any factoring or receivables financing arrangement. All other terms, including the interest rate of 11% per annum, remain unchanged.
New auditor
The general meeting resolved, in accordance with the board's proposal, to dismiss Ernst & Young Aktiebolag as the company’s auditor and to elect Forvis Mazars AB as new auditor until the end of the next annual general meeting.